Biotech Values

[DewDiligence]

Re: AMRN sales outlook

There is no reason why should Rx further go up, as they did in last few months.

AMRN is guiding to 2020 sales of $650-700M:

https://finance.yahoo.com/news/amarin-receives-fda-approval-vascepa-214907263.html

If we deduct AMRN’s Jan-Sep 2019 nine-month sales of $286.5M from the new full-year 2019 guidance of $410-425M, the implicit sales guidance for 4Q19 is $123.5-138.5M. The midpoint of this 4Q19 range is $131M, which annualizes to $524M.

Thus, the midpoint of AMRN’s 2020 guidance, $675M, represents a 29% increase from the 4Q19 run rate.